REG - CelLBxHealth PLC - MSA with Global Pharmaceutical Company

CellbxhealthAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260529:nRSc1353Ga&default-theme=true

RNS Number : 1353G  CelLBxHealth PLC  29 May 2026

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the EU Market Abuse
Regulation (596/2014) as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018, as amended. Upon the publication of
this announcement via a regulatory information service, this information is
considered to be in the public domain.

 

 

CelLBxHealth plc

 ("CelLBxHealth" or "the Company")

 

Master Services Agreement with Global Pharmaceutical Company

CTC-powered analytics for drug discovery and development

 

Guildford, UK and Plymouth Meeting, U.S. - 29 May 2026 - CelLBxHealth plc
(AIM: CLBX), a CTC intelligence company specialising in innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology, announces that it has entered into a Master Services Agreement with
AstraZeneca.

 

The agreement establishes CelLBxHealth as a qualified service provider to
AstraZeneca, enabling the Company to support drug discovery and development
through CTC powered analytics of clinical trial samples using the Parsortix®
platform.

 

Peter Collins, Chief Executive Officer of CelLBxHealth, commented: "We are
delighted to enter into this Master Services Agreement which enables
AstraZeneca to access our capabilities across their development pipeline. We
look forward to delivering strong and productive outcomes through this
framework."

 

For further information:

 

 CelLBxHealth plc                                investor@cellbxhealth.com

 Peter Collins, Chief Executive Officer          via Walbrook PR

 Jan Groen, Executive Chairman

 Cavendish (NOMAD and Broker)

 Geoff Nash / Isaac Hooper (Corporate Finance)   +44 (0) 20 7220 0500

 Sunila de Silva (Corporate Broking)

 Nigel Birks (Life Science Specialist Sales)

 Walbrook PR (Investor and Media Relations)      Tel: +44 (0)20 7933 8780 or CelLBx@walbrookpr.com

 Paul McManus / Alice Woodings                   Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

Notes for editors

 

About CelLBxHealth plc

CelLBxHealth plc is a CTC intelligence company specialising in innovative
circulating tumour cell (CTC) solutions for use in research, drug development
and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs
from blood and can be integrated with existing laboratory instruments for
comprehensive downstream analysis - including whole-cell imaging, proteomic
profiling and full genomic workflows.

 

Commercial focus spans three revenue streams - Product Sales of the Parsortix
platform and consumables through CRO and clinical lab partnerships, Laboratory
Services including clinical trial support and assay development delivered from
a GCLP-compliant UK facility, and Lab Developed Tests (LDTs), pursued through
a combination of strategic partnerships and in-house development.

 

For more information, visit https://cellbxhealth.com/
(https://cellbxhealth.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRKVLFLQELFBBV



            Copyright 2019 Regulatory News Service, all rights reserved